But "cancer drugs offering low or no added benefits accounted for $6.7 billion in post-rebate Medicare spending in 2022 and cost more per beneficiary than high-added-benefit drugs, suggesting ...

The other promising drug is in their growing oncology pipeline, as Zaltrap has given way to Libtayo, their treatment for metastatic melanoma. Libtayo was originally marketed with Sanofi ...

Establishment reflects the clinical progress of IMM-1-104 and its promise in pancreatic cancer - - Follows recent Orphan Drug designation ... beyond well-known names. Despite being considered ...

CHICAGO - MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company with a market capitalization of $46.71 million, announced today that the USAN Council has approved ...

The first checkpoint inhibitor that was cleared by the U.S. Food and Drug Administration (FDA) is ipilimumab, known by its brand name Yervoy – developed and ... and American biotech Regeneron ...

Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...

Occasionally, drug names are short and snappy. But more often, they seem more like something from Greek or Norse mythology. While these names may seem overwhelming at first, they're chosen with ...

Sanofi’s cancer immunotherapy Libtayo (cemiplimab ... patients whose tumours have high PD-L1 expression brings the drug into competition with Merck & Co’s Keytruda (pembrolizumab), which ...

Sanofi’s treatment for hemophilia that can be administered as infrequently as once every other month, was approved by the US ...